|
Recent advances in the pathogenesis and treatment of paroxysmal nocturnal hemoglobinuria
|
Feb 2016
|
F1000Res
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Recent advances in the management of therapy-related myelodysplastic syndromes and acute myeloid leukemia.
|
Jan 2013
|
Curr Opin Hematol
|
myelodysplastic syndromes (MDS)
|
|
Real-Life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile
|
Jan 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis
|
Jun 2019
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria
|
Sep 2019
|
Therapeutic Advances in Hematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Rationale for the Clinical Application of Flow Cytometry in Patients with Myelodysplastic Syndromes
|
Aug 2012
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Rational Management Approach To Pure Red Cell Aplasia
|
Dec 2017
|
Haematologica
|
pure red cell aplasia (PRCA)
|
|
Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading?
|
Dec 2020
|
Best practice & research. Clinical haematology
|
myelodysplastic syndromes (MDS)
|
|
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
|
Jun 2016
|
J Clin Oncol
|
myelodysplastic syndromes (MDS)
|
|
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117
|
May 2017
|
J Clin Oncol
|
myelodysplastic syndromes (MDS)
|
